Sanofi Abandons Deal for Rare Disease Drug Amid FTC’s Monopoly Concerns
Sanofi is walking away from a deal to license an experimental Maze Therapeutics drug for a rare enzyme deficiency after the Federal Trade Commission challenged the transaction as anti-competitive. The…
Read More »
Amicus Therapeutics Rare Disease Combo Therapy Wins Long-Awaited FDA Nod
An Amicus Therapeutics combination treatment for the rare enzyme deficiency Pompe disease now has FDA approval, giving the drugmaker the opportunity to help patients who don’t respond to Sanofi products…
Read More »